Format

Send to

Choose Destination
Arch Neurol. 2002 Jun;59(6):972-6.

Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease.

Author information

1
Center for Experimental Therapeutics, University of Pennsylvania, BRB II/III, Room 812, 421 Curie Blvd, Philadelphia, PA 19104. domenico@spirit.gcrc.upenn.edu

Erratum in

  • Arch Neurol 2002 Sep;59(9):1475.

Abstract

BACKGROUND:

The isoprostane 8,12-iso-iPF(2alpha)-VI, a specific marker of in vivo lipid peroxidation, is increased in Alzheimer disease (AD). The pathological changes associated with AD have a long silent phase before the appearance of clinical symptoms. Several studies have shown that AD is preceded by a prodromal phase characterized by mild cognitive impairment (MCI).

OBJECTIVE:

To investigate levels of this biomarker in subjects with MCI.

DESIGN AND MAIN OUTCOME MEASURES:

Using gas chromatography-mass spectrometry analysis, we measured 8,12-iso-iPF(2alpha)-VI levels in urine, plasma, and cerebrospinal fluid of patients with AD, subjects with MCI, and cognitively normal elderly subjects.

SETTING AND PATIENTS:

Subjects attending the Memory Disorders Clinic.

RESULTS:

We found significantly higher 8,12-iso-iPF(2alpha)-VI levels in cerebrospinal fluid, plasma, and urine of subjects with MCI compared with cognitively normal elderly subjects.

CONCLUSIONS:

These results imply that individuals with MCI have increased brain oxidative damage before the onset of symptomatic dementia. Measurement of this isoprostane may identify a subgroup of patients with MCI with increased lipid peroxidation who are at increased risk to progress to symptomatic AD.

PMID:
12056933
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center